Allo-HSCT May Be Effective for Patients With Hepatosplenic T-Cell Lymphoma

There were 60% of patients with hepatosplenic T-cell lymphoma (HTCL) alive 2 years after undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), according to results of a retrospective study presented at the 2022 Tandem Meetings. These data “suggests allo-HSCT may be curative for some individuals,” the authors noted.

A rare type of mature T-cell lymphoma (MTCL), HSTCL is commonly treated with allo-HSCT or autologous HSCT, with limited data suggesting allo-HSCT may lead to better outcomes. The purpose of this study was to evaluate the outcomes of patients with HSCT who underwent either type of HSCT.

The single-center study identified 7 patients with HSTCL among all patients with MTCL at the Montefiore Medical Center. Manual chart review collected data and outcomes were assessed from the day patients underwent HSCT.

Of the 7 patients identified, 6 underwent allo-HSCT and 1 underwent autologous HSCT. The median age of patients who underwent allo-HSCT was 27, 50% were female, and Hispanic, African American, and Caucasian race/ethnicity was evenly divided among the cohort. Myeloablative conditioning was used in all patients with a known conditioning regimen.

During a median follow-up of 3.2 years, complete remission was achieved by 60%. The median overall survival (OS) was not reached, and 2-year OS rate was 60%. The patient who underwent an auto-HSCT was alive at follow-up.

Acknowledging that the sample size was small, the authors reported that CR was not associated with OS (hazard ratio [HR], 0.698; 95% CI, 0.108-27.9; P =.808) or female sex (HR, 1.22; 95% CI, 0.076-19.9; P =.592).

The authors concluded that, “In our population, allo-HSCT was an effective treatment modality for HSTCL with outcomes similar to those reported in the literature.”

Reference

Reef DK, de Castro A, Khatun F, et al. Allogeneic hematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a potentially curative option with a graft-versus-lymphoma effect. Presented at 2022 Tandem Meetings; April 23-26, 2022. Abstract 549.

This article originally appeared on Hematology Advisor